Novartis unveils new data at ESMO 2021, including compelling longest ever reported median overall survival data in advanced breast cancer, as it continues to push the boundaries of innovation
Novartis presents Phase III MONALEESA-2 study results demonstrating improved overall survival with Kisqali (ribociclib) in combination with letrozole. The analysis shows a statistically significant and clinically meaningful improvement in survival, with median OS of 63.9 months.